<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Longevity Supplement Risks on Longetivities</title><link>https://longetivities.com/tags/longevity-supplement-risks/</link><description>Recent content in Longevity Supplement Risks on Longetivities</description><generator>Hugo</generator><language>en-us</language><lastBuildDate>Thu, 16 Apr 2026 00:00:00 +0000</lastBuildDate><atom:link href="https://longetivities.com/tags/longevity-supplement-risks/feed.xml" rel="self" type="application/rss+xml"/><item><title>NAD Supplements Cancer Risk: Evidence, Mechanisms, and Guidance</title><link>https://longetivities.com/blog/nad-supplements-cancer-risk-evidence-mechanisms-and-guidance/</link><pubDate>Tue, 20 Jan 2026 00:00:00 +0000</pubDate><guid>https://longetivities.com/blog/nad-supplements-cancer-risk-evidence-mechanisms-and-guidance/</guid><description>&lt;blockquote&gt;
&lt;p&gt;&lt;strong&gt;Cluster context:&lt;/strong&gt; This article belongs to the &lt;strong&gt;The NAD+ Pathway and Energy&lt;/strong&gt; cluster. For the broader overview, start with &lt;a href="https://longetivities.com/blog/nad-precursors-guide-nr-nmn-niacin-iv-therapy-and-dosing/"&gt;NAD Precursors Guide: NR, NMN, Niacin, IV Therapy, And Dosing&lt;/a&gt;.&lt;/p&gt;
&lt;/blockquote&gt;
&lt;p&gt;Nicotinamide riboside supplements have surged in popularity among consumers seeking to combat aging and boost cellular energy. But a critical question remains: do these supplements fuel cancer cells alongside healthy tissues? The short answer is that human evidence shows no proven harm, yet preclinical mouse model data raises flags that researchers cannot dismiss. The main uncertainties center on dose translation between animals and humans, tissue-specific uptake, and the absence of long-term clinical trials measuring cancer endpoints, as changes in NAD+ metabolism may lead to differences in cancer risk.&lt;/p&gt;</description></item></channel></rss>